Keeping Track: FDA Turns Down Telesta's MCNA, Broader Use Of Vertex' Kalydeco
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Kalydeco Expands Indication Without Clinical Data; Keytruda Is Latest Bladder Cancer Approval
Keeping track of US FDA approvals last week included watching the creative and the familiar.
Vertex's VX-661 Has Positive Outlook Despite Futility Finding
Although a study testing a combo of the company's cystic fibrosis drug Kalydeco and the investigational VX-661 in patients with minimal CFTR function was ended due to futility, Vertex is on pace for a 2017 filing of the combo in three other CF subpopulations.
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
FDA wants another clinical trial for Duchenne muscular dystrophy treatment; focus moves to Sarepta's candidate, which gets committee review next week.